Literature DB >> 12394422

Pharmacokinetic antagonism of (+)-methamphetamine discrimination by a low-affinity monoclonal anti-methamphetamine antibody.

D E McMillan1, W C Hardwick, Mi Li, S M Owens.   

Abstract

Animals were trained to discriminate 5 or 10 mg/kg cocaine (rats), or 3 mg/kg (+)-amphetamine (pigeons) from saline, after which dose-response curves were determined for (+)-methamphetamine and other drugs before and after administration of a (+)-methamphetamine-specific monoclonal antibody (K(D) =250 nM). In rats trained to discriminate 10 mg/kg cocaine from saline, intravenous (+)-methamphetamine was about three times more potent as a discriminative stimulus than intraperitoneal (+)-methamphetamine. Also in these rats, intraperitoneal (+)-methamphetamine and (+)-amphetamine were about equipotent as discriminative stimuli, and were about three times more potent than intraperitoneal cocaine. In pigeons trained to discriminate 3 mg/kg intramuscular (i.m.) (+)-amphetamine from saline, (+)-methamphetamine and (+)-amphetamine were nearly equipotent, while cocaine was slightly less potent. In rats trained to discriminate 5 or 10 mg/kg cocaine from saline, intravenous administration of 1 g/kg of the antibody shifted both intravenous and intraperitoneal dose-response curves for (+)-methamphetamine discrimination approximately threefold to the right at 1 or 4 days after administration of the antibody. In pigeons trained to discriminate 3 mg/kg intramuscular (+)-amphetamine from saline, a similar shift of the (+)-methamphetamine dose-response curve to the right also lasted for 4-7 days. However, the antibody did not affect the (+)-amphetamine dose-response curve (pigeons), or the cocaine (rats) dose-response curve. The data show that a low affinity anti-(+)-methamphetamine-specific antibody can produce a specific antagonism of an effect of (+)-methamphetamine that is closely associated with its abuse.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394422     DOI: 10.1097/00008877-200209000-00019

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  13 in total

Review 1.  Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuse.

Authors:  Eric Peterson; S Michael Owens; Ralph L Henry
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

2.  Immunopharmacotherapeutic manifolds and modulation of cocaine overdose.

Authors:  Jennifer B Treweek; Amanda J Roberts; Kim D Janda
Journal:  Pharmacol Biochem Behav       Date:  2011-02-26       Impact factor: 3.533

Review 3.  Vaccines against drugs of abuse: where are we now?

Authors:  Berma Kinsey
Journal:  Ther Adv Vaccines       Date:  2014-07

4.  A vaccine against methamphetamine attenuates its behavioral effects in mice.

Authors:  Xiaoyun Y Shen; Therese A Kosten; Angel Y Lopez; Berma M Kinsey; Thomas R Kosten; Frank M Orson
Journal:  Drug Alcohol Depend       Date:  2012-09-28       Impact factor: 4.492

Review 5.  Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.

Authors:  Eric C Peterson; W Brooks Gentry; S Michael Owens
Journal:  Adv Pharmacol       Date:  2014

6.  A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats.

Authors:  Michelle L Miller; Amira Y Moreno; Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Brittani D Vaillancourt; M Jerry Wright; Kim D Janda; Michael A Taffe
Journal:  Biol Psychiatry       Date:  2012-10-23       Impact factor: 13.382

7.  Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.

Authors:  Elizabeth M Laurenzana; Misty W Stevens; John C Frank; Michael D Hambuchen; Howard P Hendrickson; Sarah J White; D Keith Williams; S Michael Owens; W Brooks Gentry
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  The Development and Characterization of an scFv-Fc Fusion-Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse.

Authors:  Charles E Hay; Laura E Ewing; Michael D Hambuchen; Shannon M Zintner; Juliana C Small; Chris T Bolden; William E Fantegrossi; Paris Margaritis; S Michael Owens; Eric C Peterson
Journal:  J Pharmacol Exp Ther       Date:  2020-04-03       Impact factor: 4.030

9.  Bioavailability of (+)-methamphetamine in the pigeon following an intramuscular dose.

Authors:  Howard P Hendrickson; William C Hardwick; D E McMillan; S Michael Owens
Journal:  Pharmacol Biochem Behav       Date:  2008-03-29       Impact factor: 3.533

Review 10.  Development of active and passive human vaccines to treat methamphetamine addiction.

Authors:  W Brooks Gentry; Daniela Rüedi-Bettschen; S Michael Owens
Journal:  Hum Vaccin       Date:  2009-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.